查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1840678

神經血管設備市場（按產品類型、適應症、最終用戶和分銷管道）—2025-2032 年全球預測

Neurovascular Devices Market by Product Type, Indication, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經血管設備市場將成長至 61.8 億美元，複合年成長率為 7.56%。

主要市場統計數據
基準年2024年 34.4億美元
預計2025年 37.1億美元
預測年份：2032年 61.8億美元
複合年成長率（%） 7.56%

對神經血管設備生態系統進行清晰的執行概述，使臨床創新與商業性和監管標準保持一致

神經血管器材領域正處於快速臨床創新與日益嚴格的醫療體系審查的交匯點，要求高階主管在做出策略決策時擁有清晰的認知。器械設計、影像整合和圍手術期護理方面的進步正在再形成臨床醫生的期望，並不斷擴展手術適應症，而付款方和採購負責人也日益要求可驗證的療效和成本效益。如今，相關人員需要簡潔、循證且全面的訊息，將技術能力與臨床終點和商業性可行性聯繫起來。

圍繞微創方法和影像引導介入的臨床發展勢頭正在提高設備性能和操作人員培訓的標準。同時，醫療保健提供者面臨著最佳化患者吞吐量的壓力，並透過顯著改善發病率和住院時間來證明資本和耗材支出的合理性。因此，投資者和企業負責人正在尋求能夠將手術創新轉化為永續應用路徑的分析。本引言將臨床、監管和商業因素結合起來，建構了更廣泛的報告框架，這些因素將決定哪些技術和提供者將在神經血管生態系統中獲得持久的吸引力。

後續章節重點介紹了變革的關鍵促進因素、影響採購和報銷決策的細分模式，以及影響市場進入和擴張的地理和競爭動態。本報告旨在為領導團隊提供清晰的敘述，指南優先排序和投資決策。

技術成熟度、監管期望和程序標準化如何重塑採用路徑和競爭優勢

由於三大力量的匯聚：技術成熟度、操作標準化以及支付方預期的轉變，神經血管器械領域正在經歷深刻變化。器械迭代越來越受到真實世界性能數據和計算模型的影響，從而加速了從一次性原型到臨床穩健平台的轉變。操作流程的改善和標準化訓練路徑正在降低患者治療結果的差異性，並推動其從小眾轉診中心向更廣泛的醫療機構推廣應用。

監管機構對臨床證據和上市後監管的期望也在不斷變化，鼓勵製造商將數據生成功能納入設備生命週期。相關人員正在尋求能夠顯著改善療效並簡化工作流程的整合解決方案。此外，供應鏈彈性和製造擴充性已成為策略重點，領導者正在投資試劑籌資策略和雙重採購，以減輕外部衝擊。

因此，市場差異化日益受到臨床證據、程序效率以及向付款人和醫院採購委員會展示價值的能力的驅動。這種轉變對產品開發藍圖、商業化模式和合作策略產生了實際的影響，迫使企業根據臨床實踐模式和報銷現實情況重新調整其研發重點和市場進入時機。

近期關稅對供應鏈、採購和夥伴關係的累積影響正在重塑採購和定價策略

近期的關稅措施和貿易政策調整，給神經血管器械供應鏈帶來了明顯的壓力點，製造商和供應商必須積極應對。影響原料進口、零件和成品器械的關稅增加了一些製造商的採購成本，促使其採取在岸製造和策略採購安排。為此，一些製造商正在重新審視供應商契約，並探索近岸外包和區域製造中心，以保持利潤的完整性和供應的連續性。

對於醫院和門診中心而言，採購成本的上升給資本配置決策帶來了壓力，並加劇了對設備利用率和每個成本指標的審查。因此，採購部門正在加強競爭性競標，延長供應商資格審查週期，而臨床團隊則面臨壓力，需要提供臨床療效改善和下游成本降低的證據來證明設備選擇的合理性。同時，關稅也凸顯了靈活分銷管道的重要性，企業紛紛在直銷、第三方分銷商和數位採購平台之間尋求多元化發展，以維持議價能力。

重要的是，政策環境也影響策略夥伴關係和許可安排。在受關稅影響的司法管轄區之外擁有製造地的公司享有相對的物流優勢，而其他公司則正在加速遷移協議和區域許可，以保持市場進入。展望未來，積極最佳化採購、調整定價策略並加強區域物流的相關人員將更有能力吸收政策引發的成本波動並保持供應可靠性。

詳細的細分分析揭示了產品架構、臨床適應症、護理環境和通路如何推動不同的採用和採購行為

神經血管器材產業的細分揭示了清晰的採用路徑和與產品類型、臨床指徵、最終用戶和分銷管道相關的不同商業性要求。產品類型包括血流改道裝置、微導管、神經血管線圈和神經血管支架，每種產品都有其獨特的工程限制和臨床效用。在血流改道裝置領域，管道栓塞平台、絲質結構和 Surpass 架構系統等裝置在輸送能力和管壁適形性方面相互競爭，而微導管則依靠親水性和 PTFE 等塗層在曲折的腦血管中實現最佳導航。線圈技術範圍從裸金屬到生物活性和水凝膠增強類型，旨在提高動脈瘤閉塞的耐久性。支架系列分為編織型和雷射切割型，以平衡徑向強度與靈活性和血管適形性。

有有效策略的公司正在將支架應用於多個領域，包括動靜脈畸形的治療、顱內動脈瘤的治療、顱內狹窄的治療以及缺血性中風的治療。同時，對於顱內動脈瘤的治療，血管內卷取、血流轉移策略和支架輔助栓塞之間的器械選擇受到動脈瘤形態和臨床風險狀況的影響。顱內狹窄的治療主要依賴球囊血管成形術和置入術，而缺血性中風的治療則涉及動脈內血栓溶解和機械血栓切除術，每種治療都需要特定的器械相容性和影像學工作流程。

終端使用者細分揭示了門診手術中心、醫院和專科診所之間購買行為的差異。門診中心的隸屬關係各不相同；醫院的範圍從初級區域醫療機構到擁有複雜介入神經放射學計畫的三級醫療中心；專科診所包括介入放射科和神經內科診所，也可能充當轉診中心。分銷管道也對市場進入和服務模式產生重大影響，包括透過現場代理商或機構合約進行的直銷、透過電子商務平台或製造商入口網站的線上銷售，以及跨零售和批發網路的第三方經銷商。要應對這種多層次的細分，需要針對每個相關人員客製化價值提案，並將設備功能與程序要求、報銷實際情況和採購模式結合。

跨區域監管、報銷和製造動態將決定世界主要醫療保健地區之間的差異化商業策略

區域動態對神經血管器材的監管格局、報銷框架和製造策略有著巨大的影響，美洲、歐洲、中東和非洲以及亞太地區各司法管轄區之間存在顯著差異。在美洲，醫院系統整合和對真實世界證據的關注正在影響報銷討論，並提升了衛生經濟學在採購談判中的重要性。該地區的醫療保健提供者通常優先考慮那些能夠展現操作效率並有可能減少住院時間的技術，這反過來又會影響商業訊息通訊和臨床試驗設計。

在歐洲、中東和非洲，監管協調工作和多樣化的報銷環境既帶來了機遇，也帶來了複雜性。製造商必須應對錯綜複雜的國家醫療保健體系和付款人要求，同時利用集中採購機會進行跨國競標。同時，亞太地區由於其診療量迅速成長且監管成熟度參差不齊，需要製定兼顧成本競爭力和可擴展臨床教育計畫的策略。在地化生產和有針對性的臨床合作已成為該地區應對價格敏感性並加速應用的常用策略。

在所有地區，跨境物流、智慧財產權考量以及在地培訓能力都在影響參與策略和夥伴關係模式。早期投資於特定區域監管規劃、本地化臨床證據產生和供應鏈冗餘的利益相關人員更有可能獲得更可靠的市場進入，並促進更深入的臨床醫生參與，從而提高在不同地域的醫療保健生態系統中持續採用的可能性。

產品差異化、策略聯盟和卓越營運如何塑造競爭優勢和長期臨床醫生偏好

活躍於神經血管器材領域的公司之間的競爭動態主要圍繞著產品差異化、實證醫學證據產生以及拓展核心技術臨床效用的策略聯盟。老牌器材製造商通常利用其廣泛的產品組合，提供包含儀器、影像處理軟體和培訓服務的捆綁式解決方案，從而降低尋求整合服務的醫院系統的採用門檻。相較之下，專業公司和新興企業通常專注於狹窄的創新方向，例如新型血流路徑導流支架或先進的線圈化學技術，以建立臨床驗證點並吸引合作或收購興趣。

策略交易、授權協議和共同開發夥伴關係是擴大技術規模、加快市場准入的有效途徑，尤其是在監管和臨床檢驗週期較長的情況下。與領先的介入神經放射學中心合作設計手術流程的公司可以獲得早期採用和真實世界的數據流，從而支持付款人談判。同樣，與影像和軟體供應商合作，使醫療設備製造商能夠將分析和結果追蹤納入其價值提案。

投資於製造品質系統、強大的上市後監管和響應迅速的現場支援的公司更有可能贏得臨床醫生的信任並維護與醫療機構的合約。為了應對採購的複雜性並展現對共用患者結果目標的承諾，越來越多的公司開始採用定價靈活性、捆綁銷售和基本契約。最終，那些將技術差異化與清晰的證據產生路徑和可靠的服務交付相結合的公司將最有可能獲得長期的臨床青睞。

為醫療設備製造商和醫療保健提供者提供實用的策略手冊，以協調臨床證據、製造彈性和定製商業化，從而加速採用

產業領導者應採取多管齊下的策略，將研發重點與可證明的臨床價值結合，同時增強供應鏈的韌性和商業性敏捷性。首先，優先考慮旨在解答付款人和醫院決策者關於療效和抵消成本問題的臨床證據項目，確保研究終點符合現實世界的決策標準。其次，將資料收集和分析功能嵌入到設備和上市後註冊中，以獲得持續的績效洞察，支持報銷討論和迭代產品改進。

第三，多元化您的製造和採購佈局，以緩解政策和物流中斷的影響，並考慮區域夥伴關係和授權許可，以保持市場連續性。第四，透過為門診中心、三級醫院和專科診所提供差異化的價值提案，使其反映各自的臨床工作流程和採購限制，從而使您的市場策略與最終用戶細分保持一致。第五，擴展您的商業模式，包括靈活的合約、捆綁產品和培訓夥伴關係，以減少採用摩擦，並協調供應商和製造商之間的獎勵。

最後，我們致力於與影像和軟體供應商、臨床領導者以及分銷合作夥伴建立合作關係，以建立全面的手術解決方案。透過將有針對性的臨床專案與富有彈性的營運和自適應商業化相結合，組織可以加速應用，並向整個神經血管生態系統的相關人員展示長期價值。

嚴格的混合方法研究途徑，結合專家訪談、監管分析和臨床證據綜合來支持策略決策

本報告所依據的研究結合了與臨床專家、採購主管和設備管理人員的初步定性交流，以及對監管指南和同行評審臨床文獻的系統分析。主要訪談對象包括介入神經科、介入神經放射學放射科醫生、醫院採購經理和產品開發主管，重點關注已發表資訊來源中未一致描述的實踐操作和決策因素。調查團隊將訪談結果與監管備案文件、設備標籤資訊和臨床註冊結果進行交叉比對，以檢驗觀察到的趨勢並識別新出現的應用障礙。

二次研究包括對臨床試驗、系統綜述和衛生技術評估報告進行結構化審查，以確定設備在適應症範圍內的臨床應用背景。供應鏈分析利用公開的貿易數據、製造足跡和企業資料，繪製關稅和採購的潛在影響點。此外，該調查方法結合了情境規劃，以考慮供應鏈、報銷和法規的結合如何影響採購動態，但未提供具體的市場規模或預測。

整個調查方法都強調可重複性和透明度。訪談方案和納入標準均已標準化，資料來源也進行了交叉引用以減少偏差。定性洞察與文獻檢驗相結合，提供了堅實的依證，旨在為神經血管器械領域的相關人員提供策略和產業計畫的參考。

簡潔的綜合策略要點，協調創新、證據生成和營運彈性，確保持久的臨床應用

本分析中提出的累積見解明確指出，相關人員必須迅速且周到地採取行動。器械設計和操作實踐的技術進步正在拓展臨床選擇，但其應用取決於可證實的療效、清晰的定價和可靠的供應。監管預期和付款人審查日益凸顯了整合證據策略和上市後資料收集的重要性，而貿易政策的變化則強化了多元化採購和區域製造策略的價值。

對於決策者來說，將產品開發與臨床醫生、付款人和醫院採購方的資訊需求結合才是未來的發展方向。這意味著要優先考慮能夠產生可操作結果資料的臨床項目，設計能夠減少採購摩擦的商業模式，並投資於支援培訓和設備生命週期管理的服務能力。將技術差異化與營運韌性和實證商業化相結合的組織，將創造永續的優勢，並為臨床選擇提供清晰的路徑。

總而言之，神經血管器材的市場格局蘊藏著巨大的機遇，但要抓住機遇，需要在研發、監管、生產和上市執行方面製定協調一致的策略。相關人員如果立即採取行動，加強證據產生、供應鏈靈活性和商業性參與協調，將最有可能將創新轉化為持續的臨床和商業性成功。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 採用下一代生物可吸收支架減少長期血管炎症
  • 將人工智慧和機器學習融入神經血管介入規劃
  • 開發可進入遠端腦血管的微導管技術
  • 擴大大血管急性缺血性腦中風血栓除去裝置的適應症
  • 引入聚合物塗層彈簧圈，以提高複雜解剖結構中動脈瘤閉塞的耐久性
  • 擴展遠端醫療功能，實現複雜神經介入手術的遠端監控
  • 患者專用 3D 列印血管模型的進展可最佳化手術結果

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章神經血管設備市場（依產品類型）

  • 導流裝置
    • 管道栓塞裝置
    • 絲綢裝置
    • 超越裝置
  • 微導管
    • 親水塗層
    • PTFE塗層
  • 神經血管線圈
    • 裸露金屬線圈
    • 生物活性線圈
    • 水凝膠線圈
  • 神經血管支架
    • 編織支架
    • 雷射切割支架

第9章神經血管設備市場（按適應症）

  • 動靜脈畸形
    • 黏性栓塞劑
    • 縞瑪瑙
  • 顱內動脈瘤
    • 血管內彈簧圈栓塞術
    • 流量轉換
    • 支架輔助彈簧圈栓塞術
  • 顱內狹窄
    • 球囊血管成形術
    • 支架置入術
  • 缺血性中風
    • 動脈內血栓溶解
    • 機械血栓切除術

第 10 章神經血管設備市場（依最終用戶）

  • 門診手術中心
    • 醫院相關中心
    • 獨立中心
  • 醫院
    • 基層醫院
    • 三級醫療機構
  • 專科診所
    • 介入放射科診所
    • 神經科診所

第 11 章神經血管設備市場（依通路）

  • 直銷
    • 現場負責人
    • 醫院合約
  • 網上銷售
    • 電商平台
    • 製造商網站
  • 第三方經銷商
    • 零售
    • 批發商

第 12 章神經血管設備市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章神經血管設備市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章神經血管設備市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Medtronic plc
    • Stryker Corporation
    • Johnson & Johnson Services, Inc.
    • Penumbra, Inc.
    • Terumo Corporation
    • Boston Scientific Corporation
    • MicroPort Scientific Corporation
    • Cordis LLC
    • Siemens Healthineers AG
    • Asahi Intecc Co., Ltd.
Product Code: MRR-0360AB17E1FE

The Neurovascular Devices Market is projected to grow by USD 6.18 billion at a CAGR of 7.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.44 billion
Estimated Year [2025] USD 3.71 billion
Forecast Year [2032] USD 6.18 billion
CAGR (%) 7.56%

A clear executive overview of the neurovascular devices ecosystem that aligns clinical innovation with commercial and regulatory decision criteria

The neurovascular devices domain sits at the intersection of rapid clinical innovation and heightened health system scrutiny, demanding clarity for executives making strategic choices. Advances in device design, imaging integration, and periprocedural care have reshaped clinician expectations and broadened procedural indications, while payers and procurement officers increasingly demand demonstrable outcomes and cost-effectiveness. Stakeholders now require concise, evidence-based syntheses that link technological capabilities to clinical endpoints and commercial viability.

Clinical momentum around minimally invasive approaches and imaging-guided interventions has raised the bar for device performance and operator training. Concurrently, healthcare providers face pressure to optimize patient throughput and justify capital and consumable expenditures through measurable improvements in morbidity and length of stay. Investors and corporate strategists are therefore looking for analyses that translate procedural innovation into sustainable adoption pathways. This introduction frames the broader report by aligning clinical, regulatory, and commercial vectors that will determine which technologies and providers gain enduring traction in the neurovascular ecosystem.

Throughout the subsequent sections, the report zeroes in on the major drivers of change, the segmentation patterns that influence procurement and reimbursement decisions, and the regional and competitive dynamics that shape market entry and expansion. The aim is to provide leadership teams with a coherent narrative that guides prioritization and investment decisions in a complex, fast-evolving field.

How technological maturation, regulatory expectations, and procedural standardization are reshaping adoption pathways and competitive advantages

The landscape for neurovascular devices is experiencing transformative shifts driven by three converging forces: technological maturation, procedural standardization, and shifting payer expectations. Device iterations are increasingly informed by real-world performance data and computational modeling, which in turn accelerate the transition from single-use prototypes to clinically robust platforms. Procedural refinements and standardized training pathways are reducing variability in patient outcomes, pushing adoption from niche referral centers toward broader institutional settings.

Regulatory authorities are also evolving their expectations for clinical evidence and post-market surveillance, prompting manufacturers to embed data-generation capabilities into device lifecycles. This regulatory pressure is catalyzing partnerships between device makers and imaging or software vendors, as stakeholders seek integrated solutions that offer measurable outcome improvements and streamlined workflows. In addition, supply chain resilience and manufacturing scalability have become strategic priorities; leaders are investing in reagent sourcing strategies and dual-sourcing to mitigate external shocks.

The cumulative effect is a marketplace where differentiation increasingly rests on clinical evidence, procedural efficiency, and the capacity to demonstrate value to payers and hospital procurement committees. These shifts have practical implications for product development roadmaps, commercialization models, and collaboration strategies, and they necessitate that companies recalibrate R&D priorities and market entry timing to align with both clinical practice patterns and reimbursement realities.

The cumulative supply chain, procurement, and partnership implications of recent tariff activity that are reshaping sourcing and pricing strategies

Recent tariff measures and trade policy adjustments have created discernible pressure points across the neurovascular devices supply chain that manufacturers and providers must navigate. Tariffs influencing raw material imports, componentry, and finished devices have raised procurement costs for some manufacturers and incentivized onshore manufacturing and strategic sourcing arrangements. In response, several manufacturers have re-evaluated supplier contracts and explored nearshoring and regional manufacturing hubs to preserve margin integrity and supply continuity.

For hospitals and ambulatory centers, the pass-through effects of increased procurement costs have pressured capital allocation decisions and brought greater scrutiny to device utilization and cost-per-case metrics. As a result, purchasing departments are intensifying competitive bidding and lengthening vendor qualification cycles, while clinical teams are being asked to justify device selection through evidence demonstrating improved clinical outcomes or reduced downstream costs. At the same time, tariffs have heightened the importance of flexible distribution channels; organizations are diversifying between direct sales, third-party distributors, and digital procurement platforms to retain negotiating leverage.

Importantly, the policy environment has also influenced strategic partnerships and licensing arrangements. Firms with manufacturing footprints outside tariff-impacted jurisdictions have gained relative logistical advantages, while others have accelerated transfer agreements and regional licensing to maintain market access. Moving forward, stakeholders who proactively optimize sourcing, adapt pricing strategies, and strengthen regional logistics will be better positioned to absorb policy-induced cost variability and sustain supply reliability.

In-depth segmentation analysis revealing how product architectures, clinical indications, care settings, and distribution routes drive distinct adoption and procurement behaviors

Segmentation within the neurovascular devices space reveals distinct pathways to adoption and distinct commercial imperatives tied to product type, clinical indication, end user, and distribution channel. Product typology spans flow diversion devices, microcatheters, neurovascular coils, and neurovascular stents, each carrying unique engineering constraints and clinical utility. Within flow diversion, devices like pipeline embolization platforms, silk-style constructs, and surpass-architecture systems compete on deliverability and wall apposition, while microcatheters rely on coatings such as hydrophilic and PTFE to optimize navigation through tortuous cerebral vasculature. Coil technologies range from bare metal to bioactive and hydrogel-enhanced variants that aim to improve aneurysm occlusion durability. Stent families, divided between braided and laser-cut architectures, balance radial strength against flexibility and vessel conformability.

Clinical indication segmentation further differentiates adoption dynamics across arteriovenous malformation interventions, intracranial aneurysm treatments, intracranial stenosis management, and ischemic stroke therapies. AVM interventions pivot on the selection of glue embolic agents versus Onyx-based systems, whereas intracranial aneurysm care involves choices among endovascular coiling, flow diversion strategies, and stent-assisted coiling, with device selection influenced by aneurysm morphology and clinical risk profiles. Intracranial stenosis care leans on balloon angioplasty and stenting techniques, and ischemic stroke pathways include intraarterial thrombolysis and mechanical thrombectomy systems, each demanding specific device compatibilities and imaging workflows.

End-user segmentation highlights differentiated purchasing behaviors across ambulatory surgical centers, hospitals, and specialty clinics. Ambulatory centers vary by affiliation status, hospitals range from primary community facilities to tertiary care centers with complex neurointerventional programs, and specialty clinics encompass interventional radiology and neurology clinics that may act as referral hubs. Distribution channels also cast significant influence on market access and service models, with direct sales supported by field representatives and institutional contracts, online sales through e-commerce platforms and manufacturer web portals, and third-party distributors spanning retail and wholesale networks. Navigating this layered segmentation requires tailored value propositions for each stakeholder, aligning device features with procedural requirements, reimbursement realities, and procurement models.

Cross-regional regulatory, reimbursement, and manufacturing dynamics that determine differentiated commercial strategies across major global healthcare regions

Regional dynamics exert a powerful influence on regulatory pathways, reimbursement frameworks, and manufacturing strategies across the neurovascular devices landscape, with material differences observable between the Americas, Europe, Middle East & Africa, and Asia-Pacific jurisdictions. In the Americas, consolidation in hospital systems and a strong emphasis on real-world evidence are shaping reimbursement discussions and elevating the importance of health economics in procurement conversations. Providers in this region often prioritize technologies that demonstrate procedural efficiency and the potential to reduce length of stay, which in turn affects commercial messaging and clinical trial design.

In Europe, Middle East & Africa, regulatory harmonization efforts and variable reimbursement environments create both opportunities and complexities. Manufacturers must navigate a mosaic of national health systems and payer requirements, while also capitalizing on centralized procurement opportunities for cross-border tenders. Meanwhile, the Asia-Pacific region presents a mix of rapidly expanding procedural volumes and differing regulatory maturation, prompting strategies that balance cost competitiveness with scalable clinical education programs. Localization of manufacturing and targeted clinical partnerships have become common tactics in the region to accelerate adoption while addressing pricing sensitivity.

Across all regions, cross-border logistics, intellectual property considerations, and regional training capabilities inform both entry strategies and partnership models. Stakeholders that invest early in region-specific regulatory planning, localized clinical evidence generation, and supply chain redundancy tend to secure more reliable market access and foster deeper clinician engagement, thereby improving the odds of sustained adoption across geographically diverse healthcare ecosystems.

How product differentiation, strategic alliances, and operational excellence are shaping competitive advantage and long-term clinician preference

Competitive dynamics among companies active in the neurovascular devices sector center on product differentiation, evidence generation, and strategic collaborations that extend the clinical utility of core technologies. Established device manufacturers often leverage broad portfolios to offer bundled solutions that include devices, imaging software, and training services, thereby lowering the barrier to adoption for hospital systems seeking integrated offerings. In contrast, specialized firms and startups typically focus on narrow innovation vectors-such as novel flow diversion scaffolds or advanced coil chemistries-to establish clinical proof points and attract partnership or acquisition interest.

Strategic transactions, licensing agreements, and co-development partnerships are prominent routes to scale technology and accelerate market entry, particularly where regulatory or clinical validation timelines are lengthy. Companies that align with leading neurointerventional centers to co-design procedural workflows gain early adopters and real-world data streams that support payer discussions. Similarly, alliances with imaging and software vendors enable device makers to incorporate analytics and outcome tracking into their value proposition.

Operational excellence remains a differentiator; firms that invest in manufacturing quality systems, robust post-market surveillance, and responsive field support tend to sustain clinician trust and institutional contracts. Pricing flexibility, bundled contracting, and outcomes-based agreements are increasingly employed by companies to address procurement complexity and to demonstrate commitment to shared patient outcome goals. Ultimately, the firms that combine technical differentiation with clear pathways to evidence generation and dependable service delivery will be best positioned to capture long-term clinical preference.

A pragmatic strategic playbook for device makers and providers to align clinical evidence, manufacturing resilience, and tailored commercialization to accelerate adoption

Industry leaders should adopt a multi-pronged strategy that aligns R&D priorities with demonstrable clinical value, while simultaneously reinforcing supply chain resilience and commercial agility. First, prioritize clinical evidence programs that are designed to answer payer and hospital decision-maker questions about outcomes and cost offsets, ensuring that study endpoints map to real-world decision criteria. Second, embed data capture and analytics capabilities into devices and post-market registries to generate ongoing performance insights that support reimbursement discussions and iterative product improvements.

Third, diversify manufacturing and procurement footprints to mitigate policy or logistic disruptions, and consider regional partnerships or licensing to preserve market continuity. Fourth, tailor go-to-market approaches to end-user segmentation by creating differentiated value propositions for ambulatory centers, tertiary hospitals, and specialty clinics that reflect each setting's clinical workflows and purchasing constraints. Fifth, expand commercial models to include flexible contracting, bundled offerings, and training partnerships that reduce adoption friction and align incentives between providers and manufacturers.

Finally, invest in collaborative relationships with imaging and software providers, clinical leaders, and distribution partners to create comprehensive procedural solutions. By coupling targeted clinical programs with resilient operations and adaptive commercialization, organizations can both accelerate adoption and demonstrate long-term value to stakeholders across the neurovascular ecosystem.

A rigorous mixed-methods research approach combining expert interviews, regulatory analysis, and clinical evidence synthesis to support strategic decision-making

The research underpinning this report synthesizes primary qualitative engagement with clinical experts, procurement leaders, and device executives alongside systematic analysis of regulatory guidance and peer-reviewed clinical literature. Primary interviews were conducted with interventional neurologists, neurointerventional radiologists, hospital purchasing managers, and product development leaders to surface operational realities and decision drivers that do not consistently appear in published sources. The research team triangulated interview findings with regulatory filings, device labeling information, and clinical registry outcomes to validate observed trends and to identify emerging adoption barriers.

Secondary research included a structured review of clinical trials, systematic reviews, and health technology assessment reports to establish the clinical context for device usage across indications. Supply chain analysis drew on publicly available trade data, manufacturing footprints, and corporate disclosures to map likely tariff and sourcing exposure points. In addition, the methodology incorporated scenario planning to examine how supply chain, reimbursement, and regulatory permutations could affect procurement dynamics, without projecting specific market sizes or forecasts.

Throughout, the methodology emphasized reproducibility and transparency. Interview protocols and inclusion criteria were standardized, and data sources were cross-referenced to reduce bias. The combination of qualitative insight and document-based verification yields a robust evidence base designed to inform strategy and operational planning for stakeholders engaged in the neurovascular devices domain.

A concise synthesis of strategic imperatives that align innovation, evidence generation, and operational resilience to secure durable clinical adoption

The cumulative insights presented across this analysis paint a clear imperative for stakeholders to act with both speed and deliberation. Technological progress in device design and procedural practice is expanding clinical options, but adoption will hinge on demonstrable outcomes, pricing clarity, and supply reliability. Regulatory expectations and payer scrutiny are elevating the importance of integrated evidence strategies and post-market data capture, while trade policy shifts are reinforcing the value of diversified sourcing and regional manufacturing strategies.

For decision-makers, the path forward requires aligning product development with the information needs of clinicians, payers, and hospital purchasers. This means prioritizing clinical programs that generate actionable outcomes data, designing commercial models that reduce procurement friction, and investing in service capabilities that support training and device lifecycle management. Organizations that combine technical differentiation with operational resilience and evidence-driven commercialization will create durable advantages and clearer pathways to clinical preference.

In sum, the neurovascular devices landscape presents significant opportunity, but realizing that opportunity demands coordinated strategies across R&D, regulatory planning, manufacturing, and go-to-market execution. Stakeholders who act now to shore up evidence generation, supply chain flexibility, and tailored commercial engagement will be best positioned to translate innovation into sustained clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of next-generation bioresorbable stents reducing long-term vessel inflammation
  • 5.2. Integration of artificial intelligence and machine learning in neurovascular intervention planning
  • 5.3. Development of microcatheter technologies enabling access to distal cerebral vasculature
  • 5.4. Expansion of thrombectomy device indications to treat large vessel acute ischemic strokes
  • 5.5. Emergence of polymer-coated coils for enhanced aneurysm occlusion durability in complex anatomies
  • 5.6. Growth of telemedicine-enabled remote proctoring for complex neurointerventional procedures
  • 5.7. Advancements in patient-specific 3D-printed vascular models to optimize surgical outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Devices Market, by Product Type

  • 8.1. Flow Diversion Devices
    • 8.1.1. Pipeline Embolization Devices
    • 8.1.2. Silk Devices
    • 8.1.3. Surpass Devices
  • 8.2. Microcatheters
    • 8.2.1. Hydrophilic Coated
    • 8.2.2. PTFE Coated
  • 8.3. Neurovascular Coils
    • 8.3.1. Bare Metal Coils
    • 8.3.2. Bioactive Coils
    • 8.3.3. Hydrogel Coils
  • 8.4. Neurovascular Stents
    • 8.4.1. Braided Stents
    • 8.4.2. Laser Cut Stents

9. Neurovascular Devices Market, by Indication

  • 9.1. Arteriovenous Malformation
    • 9.1.1. Glue Embolic Agents
    • 9.1.2. Onyx
  • 9.2. Intracranial Aneurysm
    • 9.2.1. Endovascular Coiling
    • 9.2.2. Flow Diversion
    • 9.2.3. Stent Assisted Coiling
  • 9.3. Intracranial Stenosis
    • 9.3.1. Balloon Angioplasty
    • 9.3.2. Stenting
  • 9.4. Ischemic Stroke
    • 9.4.1. Intraarterial Thrombolysis
    • 9.4.2. Mechanical Thrombectomy

10. Neurovascular Devices Market, by End User

  • 10.1. Ambulatory Surgical Centers
    • 10.1.1. Hospital Affiliated Centers
    • 10.1.2. Independent Centers
  • 10.2. Hospitals
    • 10.2.1. Primary Hospitals
    • 10.2.2. Tertiary Care Hospitals
  • 10.3. Specialty Clinics
    • 10.3.1. Interventional Radiology Clinics
    • 10.3.2. Neurology Clinics

11. Neurovascular Devices Market, by Distribution Channel

  • 11.1. Direct Sales
    • 11.1.1. Field Representatives
    • 11.1.2. Hospital Contracts
  • 11.2. Online Sales
    • 11.2.1. E Commerce Platforms
    • 11.2.2. Manufacturer Websites
  • 11.3. Third Party Distributors
    • 11.3.1. Retail Distributors
    • 11.3.2. Wholesale Distributors

12. Neurovascular Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurovascular Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurovascular Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Stryker Corporation
    • 15.3.3. Johnson & Johnson Services, Inc.
    • 15.3.4. Penumbra, Inc.
    • 15.3.5. Terumo Corporation
    • 15.3.6. Boston Scientific Corporation
    • 15.3.7. MicroPort Scientific Corporation
    • 15.3.8. Cordis LLC
    • 15.3.9. Siemens Healthineers AG
    • 15.3.10. Asahi Intecc Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEUROVASCULAR DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROVASCULAR DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROVASCULAR DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SILK DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SURPASS DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PTFE COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BARE METAL COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BIOACTIVE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HYDROGEL COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROVASCULAR STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BRAIDED STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY LASER CUT STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY GLUE EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONYX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ENDOVASCULAR COILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENT ASSISTED COILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRACRANIAL STENOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY BALLOON ANGIOPLASTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY STENTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ISCHEMIC STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTRAARTERIAL THROMBOLYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL AFFILIATED CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY PRIMARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY INTERVENTIONAL RADIOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY FIELD REPRESENTATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY HOSPITAL CONTRACTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RETAIL DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RETAIL DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL NEUROVASCULAR DEVICES MARKET SIZE, BY RETAIL DISTRIBUTORS,